XML 252 R195.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Legal and arbitral proceedings (Details) $ in Thousands, € in Millions, $ in Millions |  |  | 1 Months Ended | 12 Months Ended | 60 Months Ended | 72 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 03, 2022 | May 14, 2013 EUR (€) | Sep. 30, 2022 expert | Jul. 31, 2021 manufacturer | Feb. 28, 2021 USD ($) | Sep. 30, 2017 EUR (€) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 EUR (€) lawsuit action | Dec. 31, 2021 trial | Jun. 30, 2021 proceeding | Dec. 31, 2023 EUR (€) action lawsuit | Dec. 31, 2023 EUR (€) lawsuit case action | Dec. 31, 2024 EUR (€) trial claim manufacturer complaint plaintiff family case lawsuit person children | Dec. 31, 2023 AUD ($) lawsuit action | Dec. 31, 2022 EUR (€) claimant case family | Dec. 06, 2022 plaintiff cancer | Nov. 30, 2022 person | Aug. 20, 2022 ruling | Mar. 31, 2022 patient | Dec. 31, 2014 complaint | Nov. 18, 2014 patent | Dec. 31, 1997 EUR (€)
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions for product liability risks, litigation and other |  |  |  |  |  |  |  | € 1,283.0 |  |  | € 1,283.0 | € 1,283.0 | € 1,676.0 |  | € 1,652.0 |  |  |  |  |  |  |
Environmental risks |  |  |  |  |  |  |  | € 493.0 |  |  | € 493.0 | € 493.0 | € 474.0 |  | € 526.0 |  |  |  |  |  |  |
Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of first instance rulings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  | 7 |  |  |  |
Action for which we are defendant | Product liabilities | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation amount payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 0.1 |  |  |  |  |  |  |
Action for which we are defendant | Product liabilities | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation amount payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 0.5 |  |  |  |  |  |  |
Sanofi Pasteur Hepatitis B Vaccine product litigation | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of civil individual actions | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  | 180 |  |  |  |  |  |  |  |  |
Number of ongoing lawsuits | lawsuit |  |  |  |  |  |  |  | 4 |  |  | 4 | 4 |  | 4 |  |  |  |  |  |  |  |
Taxotere product litigation in the US | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of bellweather trial held | trial |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Zantac litigation in the US | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  |  |  |  |  |  |  |  | 24,922 |  |  |  |  |  |  |  |  |
Number of cancers associated with dismissed cases | cancer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |
Number of plaintiffs who filed notices to appeal | plaintiff |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,000 |  |  |  |  |  |
Number of complaints filed | complaint |  |  |  |  |  |  |  |  |  |  |  |  | 1,623 |  |  |  |  |  |  |  |  |
Zantac litigation in Canada | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of class actions | action |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  |  |  |
Gold Bond Product litigation in the US | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of class actions | action |  |  |  |  |  |  |  | 700 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of ongoing trials | action |  |  |  |  |  |  |  | 0 |  |  | 0 | 0 |  | 0 |  |  |  |  |  |  |  |
Depakine product litigation in France | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of civil individual actions | claim |  |  |  |  |  |  |  |  |  |  |  |  | 79 |  |  |  |  |  |  |  |  |
Number of people exposed | person |  |  |  |  |  |  |  |  |  |  |  |  | 133 |  |  |  |  |  |  |  |  |
Number of lawsuits ruled on merits | lawsuit |  |  |  |  |  |  |  | 40 |  |  | 40 | 40 |  | 40 |  |  |  |  |  |  |  |
Number of families who filed a civil claim | family |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 76 |  |  |  |  |  |  |
Number of claimant | claimant |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 288 |  |  |  |  |  |  |
Number of claimant exposed | claimant |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 111 |  |  |  |  |  |  |
Number of experts | expert |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of administrative proceedings | proceeding |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Depakine product litigation in Switzerland | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of people exposed | person |  |  |  |  |  |  |  |  |  |  |  |  | 17 |  |  |  |  |  |  |  |  |
Number of families who filed a civil claim | family |  |  |  |  |  |  |  |  |  |  |  |  | 11 |  |  |  |  |  |  |  |  |
Number of action declared time-barred | person |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |
Depakine product litigation in Spain | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of ongoing trials | trial |  |  |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  |
Number of people exposed | children |  |  |  |  |  |  |  |  |  |  |  |  | 15 |  |  |  |  |  |  |  |  |
Number of patients to indemnify | patient |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |
Depakine product litigation in Belgium | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of civil individual actions | complaint |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Depakine product litigation in Ireland | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pre-action protocol cases | case |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Number of civil claims on-going | claim |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Depakine product litigation in Great Britain | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of pre-action protocol cases | case |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
Depakine product litigation in Northern Ireland | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of civil claims on-going | claim |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
Dengvaxia product litigation in the Philippines | Action for which we are defendant | Product liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases | case |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  |  |  |  |  |  |  |  |
Ramipril Canada Patent Litigation | Action for which we are a plaintiff | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of manufacturers with marketing authorization for generic version of drug | manufacturer |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  |  |  |  |  |  |  |
Praluent (Alirocumab)-related amgen patent litigation in the US | Action for which we are defendant | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patent actions initially filed | complaint |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 |
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Minimum | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduced amount of compensation claimed |  |  |  |  |  |  |  | € 137.8 |  |  | € 137.8 | € 137.8 |  | $ 223.3 |  |  |  |  |  |  |  |
Reduced amount of compensation claimed, interest included |  |  |  |  |  |  |  | 218.0 |  |  | 218.0 | 218.0 |  | 360.5 |  |  |  |  |  |  |  |
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Maximum | Patents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduced amount of compensation claimed |  |  |  |  |  |  |  | 172.9 |  |  | 172.9 | 172.9 |  | 280.2 |  |  |  |  |  |  |  |
Reduced amount of compensation claimed, interest included |  |  |  |  |  |  |  | € 294.3 |  |  | € 294.3 | € 294.3 |  | $ 487.5 |  |  |  |  |  |  |  |
Plavix Attorney General Action in Hawaii | Action for which we are defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total penalty fee incurred by defendants | $ |  |  |  |  | $ 834,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Penalty fee incurred by Sanofi | $ |  |  |  |  | $ 417,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of damages claimed by the French CNAM (French Social Security) | $ |  |  |  |  |  |  | $ 916,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Plavix Attorney General Action in Hawaii | Action For Which Sanofi Are Defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of damages claimed by the French CNAM (French Social Security) | $ |  |  |  |  |  |  | $ 458,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Plavix related litigation in France | Action for which we are defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Penalty fee incurred by Sanofi |  | € 40.6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of damages claimed by the French CNAM (French Social Security) |  |  |  |  |  | € 115.8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
340B Drug Pricing Program in the United States | Action for which we are defendant |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of other manufacturers involved in proceedings | manufacturer |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aventis Crop Science retained liabilities | Contingencies arising from certain business divestitures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate participation percentage of legacy companies in ACS | 76.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Infraserv Hoechst retained liabilities | Contingencies arising from certain business divestitures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Legal and Arbitral Proceedings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fund reserves transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 57.0
Maximum amount to be reimbursed for current and future environmental expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 143.0

X
- Definition Consideration Transferred To Fund Reserve For Indemnification Undertaking + References No definition available. + Details
Name: | sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure of legal and arbitral proceedings. + References No definition available. + Details
Name: | sny_DisclosureOfLegalAndArbitralProceedingsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity investment sold percentage. + References No definition available. + Details
Name: | sny_EquityInvestmentSoldPercentage
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Global Penalty Fee Incurred By Defendants + References No definition available. + Details
Name: | sny_GlobalPenaltyFeeIncurredByDefendants
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Litigation Amount Payable. + References No definition available. + Details
Name: | sny_LitigationAmountPayable
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum Amount To Be Reimbursed For Current And Future Environmental Expense + References No definition available. + Details
Name: | sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Environment risks. + References No definition available. + Details
Name: | sny_NonCurrentProvisionForEnvironmentRisks
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Product liability risks litigation and other. + References No definition available. + Details
Name: | sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Action Declared Time-Barred + References No definition available. + Details
Name: | sny_NumberOfActionDeclaredTimeBarred
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Administrative Proceedings + References No definition available. + Details
Name: | sny_NumberOfAdministrativeProceedings
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Bellweather Trials Held + References No definition available. + Details
Name: | sny_NumberOfBellweatherTrialsHeld
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Cancers Associated With Dismissed Cases + References No definition available. + Details
Name: | sny_NumberOfCancersAssociatedWithDismissedCases
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Cases + References No definition available. + Details
Name: | sny_NumberOfCases
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Civil Claims On-Going + References No definition available. + Details
Name: | sny_NumberOfCivilClaimsOnGoing
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Civil Individual Actions + References No definition available. + Details
Name: | sny_NumberOfCivilIndividualActions
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Claimant + References No definition available. + Details
Name: | sny_NumberOfClaimant
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Claimant Exposed + References No definition available. + Details
Name: | sny_NumberOfClaimantExposed
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Class Action Lawsuits + References No definition available. + Details
Name: | sny_NumberOfClassActionLawsuits
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Complaints Filed + References No definition available. + Details
Name: | sny_NumberOfComplaintsFiled
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Counter-Expertise Experts + References No definition available. + Details
Name: | sny_NumberOfCounterExpertiseExperts
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Families Who Filed A Civil Claim + References No definition available. + Details
Name: | sny_NumberOfFamiliesWhoFiledACivilClaim
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of First Instance Rulings + References No definition available. + Details
Name: | sny_NumberOfFirstInstanceRulings
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Lawsuits Ruled On Merit + References No definition available. + Details
Name: | sny_NumberOfLawsuitsRuledOnMerit
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug + References No definition available. + Details
Name: | sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Ongoing Lawsuits + References No definition available. + Details
Name: | sny_NumberOfOngoingLawsuits
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Ongoing Trials + References No definition available. + Details
Name: | sny_NumberOfOngoingTrials
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Other Manufacturers Involved In Proceedings + References No definition available. + Details
Name: | sny_NumberOfOtherManufacturersInvolvedInProceedings
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patent actions initially filed . + References No definition available. + Details
Name: | sny_NumberOfPatentActionsInitiallyFiled
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of patents allegedly infringed. + References No definition available. + Details
Name: | sny_NumberOfPatentsAllegedlyInfringed
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Patients To Indemnify + References No definition available. + Details
Name: | sny_NumberOfPatientsToIndemnify
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of People Exposed + References No definition available. + Details
Name: | sny_NumberOfPeopleExposed
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Plaintiffs. + References No definition available. + Details
Name: | sny_NumberOfPlaintiffs
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Plaintiffs Who Filed Notices To Appeal + References No definition available. + Details
Name: | sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Pre-Action Protocol Cases + References No definition available. + Details
Name: | sny_NumberOfPreActionProtocolCases
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payment Of Damages Claimed By Counterparty + References No definition available. + Details
Name: | sny_PaymentOfDamagesClaimedByCounterparty
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Penalty Fee Incurred + References No definition available. + Details
Name: | sny_PenaltyFeeIncurred
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reduced Amount Of Compensation Claimed By Filled Plaintiffs + References No definition available. + Details
Name: | sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included + References No definition available. + Details
Name: | sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_SanofiPasteurHepatitisBVaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInTheUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSwitzerlandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSpainMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInBelgiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInIrelandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInGreatBritainMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInNorthernIrelandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_DengvaxiaProductLitigationInThePhilippinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_RamiprilCanadaPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_DefendantAxis=sny_ActionForWhichWeArePlaintiffMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=sny_Patents1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_PlavixLitigationCommonwealthInAustraliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_DefendantAxis=sny_ActionForWhichSanofiAreDefendantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_PlavixRelatedLitigationInFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_A340BDrugPricingProgramInTheUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_AventisCropScienceRetainedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ContingenciesArisingFromCertainBusinessDivestituresMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_LegalAndArbitralProceedingsAxis=sny_InfraservHoechstRetainedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |